Insider trade

CFO received an award of 6,326 BIO derivative securities

Traded Sep 4, 2026 · Filed Sep 9, 2026

Bio-Rad LaboratoriesBIO

6,326
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 4, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 9, 2026

CFOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001396867-26-000004
Filed / recorded

Sep 9, 2026, 10:42 PM UTC

Added to OQRO

Oct 6, 2026, 4:40 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

BIO-RAD LABORATORIES, INC.

Issuer CIK

12208

Ticker

BIO BIO.B

Reporting person

Roop Kalyan Lakkaraju

Relationship

Officer

Officer title

EVP, Chief Financial Officer

Security

Restricted Stock Units

Table

Derivative (Table II)

Transaction date

Sep 4, 2026

Transaction code

A

Shares / units

6,326

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

6,326

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.